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Introduction: There are a large number of global clinical trials
ongoing for patients with non-small cell lung cancer (NSCLC).
Ethnic difference in toxicity has not been adequately studied.
Methods: We performed a systematic search in PubMed for ran-
domized phase II and III trials of NSCLC from January 2000 to
December 2009, examining ethnic difference in hematological tox-
icity due to cytotoxic chemotherapy. Ethnicity was classified into
Asian and non-Asian. We chose three treatment regimens used for
NSCLC globally: cisplatin plus gemcitabine (CG), cisplatin plus
vinorelbine (CV), and carboplatin plus paclitaxel (CP). We applied
sensitivity analysis to examine unreported ethnic differences in
hematological toxicities by changing the percentage of Asian pa-
tients from 0 to 18% in trials reported from the United States and
Europe.
Results: We identified 12 phase II trials and 38 phase III trials of
NSCLC with a total of 11,271 patients. Among these, 14 trials had
reported ethnic origins. Grade 3/4 toxicities were more frequently
observed in the Asian studies. On the basis of sensitivity analysis,
odds ratio of grade 3/4 neutropenia was significantly higher in Asian
patients than non-Asian, when treated with CG (OR  1.55–3.45,
p  0.001), CV (OR  2.99–4.43, p  0.001), and CP (OR 
4.79–6.22, p  0.001). Grade 3/4 anemia was also significantly
higher in Asians with CG (OR 3.10–3.27, p 0.001), CV (OR
1.99–2.43, p  0.001), and CP (OR  1.34–1.52, p  0.001–
0.004). However, no significant difference was observed in throm-
bocytopenia with CG (OR  0.66–2.04, p  0.001–1.000), CV
(OR  0.42–0.57, p  0.097–0.323), or CP (OR  1.21–1.39, p 
0.114–0.152).
Conclusions: Severe hematological toxicity was frequently ob-
served in Asian patients compared with non-Asian (mostly whites)
in the treatment of chemotherapy for NSCLC.
Key Words: Non-small cell lung cancer, Chemotherapy, Ethnic
difference, Sensitivity analysis.
(J Thorac Oncol. 2011;6: 1881–1888)
A growing number of global clinical trials are ongoing forpatients with non-small cell lung cancer (NSCLC), which
will likely be further enhanced by the recent emergence of
molecular targeting agents. Differences in toxicity because of
several chemotherapeutic agents for lung cancer among dif-
ferent ethnicity have been reported.1,2 Epidermal growth
factor receptor (EGFR)-targeting agents are the first molec-
ular targeting agents on which ethnic differences have been
intensively discussed between white and Asian patients.3,4
Ethnic difference in clinical benefit from EGFR ty-
rosine kinase inhibitors (TKIs) treatment has been empha-
sized, whereas the side effects caused by cytotoxic chemo-
therapy have not been fully studied. There is some evidence
for ethnic differences in the pharmacokinetics and in toxicity
from anticancer drugs, in particular between Asian and white
patients. It has been reported that allelic variants of genes
encoding drug-metabolizing enzymes are expressed with dif-
ferent incidences in different ethnic groups.5
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For example, irinotecan is a cytotoxic drug for treat-
ment of small cell lung cancer and NSCLC, and association
between the toxicity and single-nucleotide polymorphism has
been studied intensively about uridine diphosphate glucu-
ronosyltransferase 1A1-glucuronosyltransferase 1A1. In fact,
in comparative outcomes analysis of Japan Clinical Oncology
Group 9511 and Southwest Oncology Group (SWOG) 0124
in extensive stage small cell lung cancer, significant differ-
ences in toxicity were observed in cisplatin plus irinotecan
between the two populations.6 Grade 3 or higher neutropenia
was observed in 65% of Japanese patients, while 34% in the
United States. It is suggested that carefully planned global
clinical trials are vital to elucidate potential ethnic differences
in adverse effects.
In this study, we report an ethnic difference in toxicity
due to chemotherapy for patients with NSCLC through sys-
tematic review of the literature. Platinum-containing chemo-
therapy is still the cornerstone of treatment for patients,7 and
we chose treatment regimens that were globally used, includ-
ing cisplatin plus gemcitabine (CG), cisplatin plus vinorel-
bine (CV), and carboplatin plus paclitaxel (CP) in NSCLC.
The target ethnicity in this study was Asians and non-Asians
who were mainly white.
METHODS
Literature Search and Data Extraction
Randomized trials with chemotherapy regimens of CP,
CG, and CV in NSCLC published from January 1, 2000, to
December 31, 2009, were identified from MEDLINE. We
used keywords “nonsmall cell lung cancer,” “cisplatin,”
“gemcitabine,” “vinorelbine,” “carboplatin,” “paclitaxel,”
“phase II,” “phase III,” and “randomized trial.” The trials
with number of patients less than 50 were excluded to better
ensure reliability. Search results were limited to reports
written in the English language.
To evaluate the toxicity of chemotherapy, we excluded
reports of postoperative chemotherapy, preoperative chemo-
therapy, and chemotherapy for elderly or poor performance
status and chose the reports that used chemotherapy agents
with doses and schedules close to those in Japan. We adopted
the trials with cisplatin 75 to 80 mg/m2 and gemcitabine 1000
to 1250 mg/m2, every 3 weeks, and the trials with cisplatin 75
to 80 mg/m2 and vinorelbine 25 to 30 mg/m2. Similarly, we
adopted the trials with carboplatin area under the curve 5 to
6 mg/ml/min and paclitaxel 200 to 225 mg/m2. Trials involv-
ing radiation therapy were excluded. For each trial, data on
sample size, characteristics of ethnicity, toxicity of neutrope-
nia, anemia, and thrombocytopenia were collected. Each
study has its own measure to evaluate side effects, which
were World Health Organization criteria and the National
Cancer Institute’s common toxicity criteria version 1 to 4.
Although there is a slight difference among them, the bound-
ary of grades 2 and 3 is the same.
Literature search was performed independently by two
investigators (Y.H. and T.T.) to assess the reliability of data
extraction.
Statistical Analysis
To evaluate ethnic difference in toxicity due to chemo-
therapies, we calculated actual number of patients from
published data.
Sample distributions for the patients with and without
toxicities were tested with the 2 test and odds ratio (OR)
with its 95% confidence interval. Because a certain number of
reports did not include ethnicity information, we were uncer-
tain of the ratio of Asian patients in study population in each
clinical trial. We were also uncertain of the occurrence of
FIGURE 1. Schematic diagram of
sensitivity analysis.
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toxicity in the Asian patients. As shown in Figure 1, we used
sensitivity analysis by systematically repeating the statistical
analysis using different assumptions for the ratio of Asian
patients in clinical trials performed in the United States and
Europe. Sensitivity analysis can be used to determine how
different values of an independent variable will impact a
particular dependent variable under a given set of assump-
tions when the study involves uncertainty in data distribu-
tions.8 Ratio of ethnicity is determined based on the trials that
include ethnicity information. We applied the ranged ratios of
Asian patients to the trials in which the racial ratio was not
described. We assumed the incidence of hematological tox-
icity in Asian patients based on the actual incidence observed
in the trials selected.
As for survival, we examined whether there are any
differences in the distribution of median overall survival
between Asian and US/Europe trials using Student’s t test.
A p value less than 0.05 was considered statistically
significant, and all reported p values were obtained with
two-sided manner. All statistical analyses were performed
using SPSS 16.0 for Windows (SPSS, Inc, Chicago, IL).
RESULTS
Study Selection
The flowchart for study selection is shown in Figure 2.
We retrieved 328 articles on the regimen of CG, 216 articles
on CV, and 361 articles on carboplatin and paclitaxel. Fi-
nally, we identified 12 phase II and 38 phase III trials of
NSCLC with a total of 11,271 patients in three regimens.
All articles are listed in supplement 1 to 3B, Supplemental
Digital Content 1 to 4; http://links.lww.com/JTO/A104,
http://links.lww.com/JTO/A105, http://links.lww.com/JTO/A106,
and http://links.lww.com/JTO/A108. In the regimen of CG, we
identified four phase II trials and 14 phase III trials with a total
of 4023 patients (supplement 1, Supplemental Digital Content 1,
http://links.lww.com/JTO/A104). Two trials were performed in
Japan and China (Asian studies), and 16 trials were performed in
the United States and Europe (non-Asian studies). In CV, one
phase II trial and four phase III trials were identified with a total
of 1253 patients (supplement 2, Supplemental Digital Content 1,
http://links.lww.com/JTO/A105). Two trials were performed in
Japan, and three trials were performed in the United States and
Europe. In CP, we selected seven phase II trials and 20 phase III
trials with a total of 5995 patients (supplement 3A, 3B, Supple-
mental Digital Content 3 and 4, http://links.lww.com/JTO/A106
and http://links.lww.com/JTO/A108). Three trials were per-
formed in Asian countries including Japan, and 24 trials were
performed in the United States and Europe. With regard to
patient characteristics, median age from 56.4 to 66 years, and
good performance status ratio (Eastern Cooperative Oncology
Group 0 to 1,WorldHealthOrganization 0 to 1, orKarnofsky70)
accounted for 99.8% as a median. In the comparison of age
between Asian trials and non-Asian trials, there was no
significant difference in the three regimens; CG (p  0.64),
CV (p  0.50), and CP (p  0.82), respectively. In the
performance status, there were more patients with poor per-
formance status included in non-Asian study in the two
regimens: CG (p  0.001) and CV (p  0.001); there was no
significant difference in CP (p  0.45).
Hematological Toxicity in Asian and Non-Asian
Studies
As shown in Figure 3, grade 3/4 toxicities were more
frequently observed in the Asian studies, when the actual
number of all the patients was combined. Distribution of the
frequency of grade 3/4 toxicity is shown in Figure 4. In a
regimen of CG, neutropenia, anemia, and thrombocytopenia
FIGURE 2. Flow chart showing
the progress of trials through the
review.
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were more frequently observed in Asian studies than in
non-Asian studies with a statistical significance (p  0.001).
In a regimen of CV, neutropenia and anemia were also
significantly more frequently observed in Asian studies (p 
0.001) except thrombocytopenia (p 0.323). In a regimen of
CP, neutropenia and anemia occurred more frequently in
Asian studies (p 0.001), again excepting thrombocytopenia
(p  0.115).
Hematological Toxicity in Sensitivity Analysis
Asians in the Asian trial were Japanese and Chinese
from East Asia, whereas non-Asians were large and hetero-
geneous populations without a specified origin. We extracted
Asian and non-Asian patients from both separated Asian
trials/non-Asian trials and trials enrolling Asian and non-
Asian patients.
In a total of 50 trials of NSCLC that were identified,
only 14 trials reported ethnic origins of the study participants.
Among the 14 trials, 8 trials included Asian patients and they
showed that the ratio of Asian and non-Asian patients is
imbalanced, and the proportion of Asian patients ranged from
0.8 to 17.4% (median 6.0%).
We estimated the ratio of Asian patients in the 36
trials with unknown ethnic origins. We calculated the
hazard ratio  95% confidence interval of hematological
toxicity (Asian/non-Asian) in each regimen, varying a
putative Asian population from 0 to 18%. We adopted the
lowest frequency of each hematological toxicity observed
in actual Asian trials, and we could reduce the margin of
error to be more accurate, minimizing the possible differ-
ences in severity of hematological toxicities between
Asians and non-Asians (Figure 1). On the basis of these
assumptions, nine models were created as shown in Figure
5. x axis is the ratio of Asian, and y axis is the OR. We
showed how an OR changed as we changed the Asian
ratio. The green dotted line represents the OR of 1. As
shown in Figure 5, even if we changed the Asian ratio,
more frequent grade 3/4 neutropenia and anemia were
observed significantly in Asian patients in the three regi-
mens. However, there was no significant difference be-
tween Asian and non-Asian in frequency of severe throm-
bocytopenia.
Survival Analysis
We identified six phase II and 38 phase III trials of
NSCLC in three regimens in survival analysis. We excluded the
IRESSA Pan Asia Study trial because most of the patients in the
study were never-smokers in East Asia who had outstanding
FIGURE 3. Comparison of grades 3 and 4 hematological toxicity between combined Asian and non-Asian trials.
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good prognosis. In the comparison of overall survival by using
Student’s t test, median survival time was longer in the Asian
studies than those in non-Asian studies as shown in Figure 6
(12.2 months versus 9.6 months, p  0.012).
DISCUSSION
Global clinical trials including lung cancer have ad-
vanced year by year. Glickman et al.9 reviewed 300 articles
reporting the results of clinical trials in 1995–2005 and found
that the number of countries serving as trial sites outside the
United States more than doubled in 10 years, whereas the
proportion of trials conducted in the United States and West-
ern Europe decreased. Globalization of clinical trials may
also shorten the timeline for clinical testing.
Although it is efficient to include patients globally for
saving time and costs in completing large-scale clinical trials,
ethnic difference in treatment benefit and toxicity is becom-
ing a great concern. In IRESSA Survival Evaluation in Lung
cancer study,4 Asian patients lived longer compared with
non-Asian patients treated with gefitinib (median 9.5 versus
5.2 months). EGFR mutation is a critical biomarker for
EGFR-TKIs, and there is a higher rate of EGFR mutations in
the Asian patients than whites, 19 to 61% versus 5 to 10%.5
Ethnic difference in clinical benefit might be because of
tumor biology among different ethnicities. However, instead
of a large body of work focused on differences in clinical
benefit, we find that those in hematological toxicity have not
been fully studied. Given such a situation, we showed a
significant difference of hematological toxicity due to cyto-
toxic chemotherapy between Asian and non-Asian in a
pooled analysis on phase II and III clinical trials.
In this study, we showed that the degree of hematolog-
ical toxicities of neutropenia and anemia was significantly
different between Asian and the US/European studies. In
sensitivity analysis, we demonstrated that Asian patients had
a disadvantage in side effects compared with non-Asian
patients who were mostly whites. Grade 3/4 neutropenia and
anemia were more frequently observed in Asians in the
common chemotherapy regimens of platinum doublets
widely used in patients with NSCLC. Serious thrombocyto-
penia was also observed in CG, but not in CV and CP. It is
suggested that dose setting be carefully conducted in global
clinical trial and that dose modification according to ethnicity
be considered.
FIGURE 4. Comparison of grades 3 and 4 hematological toxicity between Asian and non-Asian trials; scatterplot.
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There is substantial interindividual variability in drug
metabolism.10 Recent evidence suggests that there is even
greater variability between individuals of different ethnicity.
A number of genetic polymorphisms that reflect ethnic dif-
ferences have been reported to affect pharmacokinetics and
pharmacodynamics.5 It is well known that pharmacokinetic
factors that determine an individual’s exposure to drugs and
metabolites affect the potential for beneficial and toxic re-
sponses to that medicine, e.g., CDA*3 for gemcitabine,11
ABCB1 for vinorelbine,12 CYP2C8 for paclitaxel,13,14 and
ERCC2, XPD for platinum compounds.2,15
Another explanation for ethnic difference is frequency
of never-smokers in patients with NSCLC between Asians
and whites. Epidemiological study showed that approxi-
mately 30% of patients with NSCLC were never-smokers in
Asians, while 7 to 8% in whites.16 In smokers, the dose-
FIGURE 5. Sensitivity analysis:
green dotted line represents the OR
of 1. Red and yellow dotted lines
represent probability with 95% con-
fidence. Yellow dotted line is the
highest probability. Red dotted line
is the lowest probability. A difference
is found when using the high figure
in Figure 3. Because this is not repre-
sentative of the entire group, it does
not show a difference among all
cases. If we use the lowest number,
we reduce the margin of error to be
more accurate. In this study, severe
neutropenia and anemia were more
frequently observed in Asians, ex-
cepting severe thrombocytopenia.
FIGURE 6. Survival and race: the compari-
son of overall survival time by using Stu-
dent’s t test.
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normalized area under the plasma concentration–time curve
of irinotecan was significantly lower compared with non-
smokers, and smokers experienced considerably less hema-
tologic toxicity.17 In addition, there was a significantly higher
incidence of grades 3 and 4 neutropenia among patients
treated with gemcitabine monotherapy without a history of
smoking than among those with a history of smoking.18
Therefore, smoking status may affect drug metabolism and
toxicity, although this is still controversial.
Neutropenia during chemotherapy has been reported to
be a predictor of longer survival in several studies.19,20 In fact,
among clinical trials analyzed in this study, we detected weak
correlation between response rates and grade 3 and 4 hema-
tological toxicities for neutropenia (data not shown). We
showed that median survival time was better in the Asian
studies than those in the non-Asian studies, although it is a
statistical disadvantage without considering size of the study.
Side effects of neutropenia shown in this study may affect the
prognosis of Asians as well. In the international First-Line
ErbituX in lung cancer study,21 the 11% of patients who were
Asian had a considerably better overall prognosis regardless
of study treatment compared with whites (median survival,
19.5 months versus 9.6 months). Again, EGFR mutations
were frequently observed in Asians, and survival benefit for
Asians seemed to be because of EGFR mutations and EGFR-
TKI treatment. Recently, Gandara et al.22 reported that tu-
mors with EGFR-activating mutations have lower expression
level of genes associated with DNA repair, such as ERCC1
and suggested that low DNA repair capacity may be a more
direct explanation for improved efficacy of platinum-based
chemotherapy in Asian populations.
There are some limitations in our study. First, our
unique methods may potentially influence publication bias.
However, our primary focus of toxicity is not associated with
end point originally designed in each clinical trial, and our
results cannot be affected by published data selected. Other
confounding factors that influence hematological toxicity also
should be considered. There was no significant difference in
age distribution between Asian trial and non-Asian trial, and
there were poorer performance status patients included in
non-Asian study, which likely relates with more side effects.
More side effects occurred in Asian trials, which included
more good performance status patients, and unbalanced per-
formance status distribution between the two study groups
cannot minimize our results. Second, the number of Asian
trials was relatively small, and the chemotherapy regimen of
cisplatin and pemetrexed was not included in this study,
which is also commonly used globally. However, no phase II
or phase III studies on cisplatin and pemetrexed conducted in
Asian countries have been reported to date. Global clinical
trials have increased, and more Asians will be enrolled in the
near future. Third, the data of each trial were not based on
individual data, and side effects are also affected by fre-
quency of examination of blood count. In addition, each study
has its own follow-up algorithm. There may be an argument
that Asian doctors conducted the test more, which leads to
more severe toxicity appearing in Asian study. However,
SWOG and Japan Multi-National Organization common arm
analysis used an identical protocol and they showed signifi-
cant difference between them, and grades 3 and 4 neutropenia
and febrile neutropenia were significantly greater than in
SWOG trial.2 This common arm analysis is a promising and
reliable method to investigate toxicity and genetic back-
grounds particularly for the study of ethnic differences. An-
other approach can be inclusion of the information of ethnic-
ity in designing clinical trials, which will be collected
individually for future meta-analysis.
In conclusion, we demonstrated that severe hematolog-
ical toxicities were more frequently observed in Asian pa-
tients compared with non-Asians who were mainly white.
This study suggests that global clinical trials should be
carefully designed and conducted to account for potential
genetic differences in the patient. Large-scale prospective
studies focused on ethnic differences are warranted for global
public benefit.
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